Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by Driehaus Capital Management LLC

Driehaus Capital Management LLC grew its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 62.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 87,078 shares of the life sciences company's stock after buying an additional 33,507 shares during the quarter. Driehaus Capital Management LLC owned 0.05% of Illumina worth $11,636,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Capital World Investors boosted its position in Illumina by 408.6% in the fourth quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock worth $2,408,721,000 after purchasing an additional 14,481,232 shares during the last quarter. Brown Advisory Inc. grew its holdings in Illumina by 54,220.9% during the fourth quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company's stock valued at $255,586,000 after purchasing an additional 1,909,118 shares during the period. Norges Bank bought a new position in shares of Illumina in the fourth quarter worth about $228,714,000. Bessemer Group Inc. grew its stake in shares of Illumina by 32,837.5% during the 4th quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company's stock valued at $180,152,000 after acquiring an additional 1,344,038 shares during the period. Finally, WCM Investment Management LLC lifted its holdings in Illumina by 26.6% during the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock valued at $551,625,000 after purchasing an additional 867,673 shares in the last quarter. Institutional investors own 89.42% of the company's stock.

Illumina Stock Performance

Illumina stock traded down $1.27 during midday trading on Tuesday, hitting $80.30. 2,341,973 shares of the company were exchanged, compared to its average volume of 2,293,418. The firm has a market capitalization of $12.71 billion, a PE ratio of -10.46, a price-to-earnings-growth ratio of 1.60 and a beta of 1.35. The business has a fifty day simple moving average of $78.85 and a two-hundred day simple moving average of $112.70. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.03 billion. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Illumina's quarterly revenue was down 1.4% compared to the same quarter last year. During the same period last year, the company posted $0.98 EPS. On average, sell-side analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analysts Set New Price Targets

ILMN has been the topic of several recent analyst reports. Piper Sandler lifted their target price on Illumina from $185.00 to $190.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. TD Cowen lowered shares of Illumina from a "buy" rating to a "hold" rating and dropped their target price for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. Canaccord Genuity Group decreased their price target on shares of Illumina from $92.00 to $87.00 and set a "hold" rating on the stock in a research note on Monday. Stephens reissued an "overweight" rating and set a $156.00 price target on shares of Illumina in a research note on Tuesday, March 11th. Finally, Robert W. Baird lowered their target price on Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a research report on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Illumina has an average rating of "Moderate Buy" and a consensus target price of $130.95.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.